- Home
- HCWC vs ALZN Comparison
HCWC vs ALZN Comparison
Compare HCWC & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWC
- ALZN
- Stock Information
- Founded
- HCWC N/A
- ALZN 2016
- Country
- HCWC
- ALZN United States
- Employees
- HCWC 450
- ALZN N/A
- Industry
- HCWC
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- HCWC
- ALZN Health Care
- Exchange
- HCWC NYSE
- ALZN Nasdaq
- Market Cap
- HCWC 5.0M
- ALZN 4.5M
- IPO Year
- HCWC N/A
- ALZN 2021
- Fundamental
- Price
- HCWC $0.42
- ALZN $3.62
- Analyst Decision
- HCWC
- ALZN Strong Buy
- Analyst Count
- HCWC 0
- ALZN 1
- Target Price
- HCWC N/A
- ALZN $180.00
- AVG Volume (30 Days)
- HCWC N/A
- ALZN 4.6M
- Earning Date
- HCWC N/A
- ALZN 07-29-2025
- Dividend Yield
- HCWC N/A
- ALZN N/A
- EPS Growth
- HCWC N/A
- ALZN N/A
- EPS
- HCWC N/A
- ALZN N/A
- Revenue
- HCWC N/A
- ALZN N/A
- Revenue This Year
- HCWC N/A
- ALZN $322.64
- Revenue Next Year
- HCWC N/A
- ALZN N/A
- P/E Ratio
- HCWC N/A
- ALZN N/A
- Revenue Growth
- HCWC N/A
- ALZN N/A
- 52 Week Low
- HCWC N/A
- ALZN $3.06
- 52 Week High
- HCWC N/A
- ALZN $135.54
- Technical
- Relative Strength Index (RSI)
- HCWC N/A
- ALZN 42.05
- Support Level
- HCWC N/A
- ALZN $3.55
- Resistance Level
- HCWC N/A
- ALZN $4.30
- Average True Range (ATR)
- HCWC 0.00
- ALZN 0.58
- MACD
- HCWC 0.00
- ALZN 0.11
- Stochastic Oscillator
- HCWC 0.00
- ALZN 7.44
About HCWC HEALTHY CHOICE WELLNESS CORP
Healthy Choice Wellness Corp is a company engaged in providing consumers with healthier daily choices with respect to nutrition and other lifestyle alternatives. The company has one reportable segment which is natural and organic retail stores.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.